Literature DB >> 11897339

Studies of the binding of a series of platinum(IV) complexes to plasma proteins.

Rachael C Dolman1, Glen B Deacon, Trevor W Hambley.   

Abstract

The platinum(IV) complexes: [PtCl(4)(en)], cis,trans-[PtCl(2)(OAc)(2)(en)], cis,trans-[PtCl(2)(OH)(2)(en)] and trans-[Pt(OH)(2)(ethmal)(en)], encompassing a range of reduction potentials and their platinum(II) analogue [PtCl(2)(en)], have been assayed for their protein binding ability in the presence of albumin, albumin and L-cysteine and RPMI 1640 tissue culture medium supplemented with foetal calf serum (RPMI/FCS). cis,trans-[PtCl(4)(en)] exhibited significant protein binding in all three experiments, in a similar fashion to the platinum(II) complex, presumably as a consequence of its rapid reduction. The remaining three platinum(IV) complexes displayed little if any protein binding, with the greatest amount of binding observed in the RPMI/FCS experiment. The extent of binding in the RPMI/FCS correlated with the reduction potentials of the complexes, with the most readily reduced species binding to the greatest extent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897339     DOI: 10.1016/s0162-0134(01)00360-9

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  15 in total

1.  Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2011-03-01       Impact factor: 5.165

2.  Risedronate metal complexes potentially active against Chagas disease.

Authors:  Bruno Demoro; Francesco Caruso; Miriam Rossi; Diego Benítez; Mercedes Gonzalez; Hugo Cerecetto; Beatriz Parajón-Costa; Jorge Castiglioni; Melina Galizzi; Roberto Docampo; Lucía Otero; Dinorah Gambino
Journal:  J Inorg Biochem       Date:  2010-08-14       Impact factor: 4.155

Review 3.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

4.  Interaction of liposome-encapsulated cisplatin with biomolecules.

Authors:  Bharat Baruah; Alexandr Surin
Journal:  J Biol Inorg Chem       Date:  2012-06-07       Impact factor: 3.358

Review 5.  The Platin-X series: activation, targeting, and delivery.

Authors:  Uttara Basu; Bhabatosh Banik; Ru Wen; Rakesh K Pathak; Shanta Dhar
Journal:  Dalton Trans       Date:  2016-08-16       Impact factor: 4.390

6.  Modulation of Ligand Fluorescence by the Pt(II)/Pt(IV) Redox Couple.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Inorganica Chim Acta       Date:  2012-01-03       Impact factor: 2.545

7.  Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents.

Authors:  Grégory Thiabaud; Guangan He; Sajal Sen; Kathryn A Shelton; Wallace B Baze; Luke Segura; Julie Alaniz; Ruben Munoz Macias; Greg Lyness; Alan B Watts; Hyun Min Kim; Hyunseung Lee; Mi Young Cho; Kwan Soo Hong; Rick Finch; Zahid H Siddik; Jonathan F Arambula; Jonathan L Sessler
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-16       Impact factor: 11.205

8.  Monofunctional and higher-valent platinum anticancer agents.

Authors:  Timothy C Johnstone; Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-06-05       Impact factor: 5.165

9.  Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery.

Authors:  Santosh Aryal; Che-Ming Jack Hu; Liangfang Zhang
Journal:  ACS Nano       Date:  2010-01-26       Impact factor: 15.881

10.  In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent.

Authors:  Ulrike Olszewski; Florian Ach; Ernst Ulsperger; Gerhard Baumgartner; Robert Zeillinger; Patrick Bednarski; Gerhard Hamilton
Journal:  Met Based Drugs       Date:  2009-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.